Continuous Glucose Monitor > 자유게시판

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

A continuous glucose monitor (CGM) is a gadget for monitoring blood glucose repeatedly instead of monitoring periodically by drawing a drop of blood from a finger. This is known as steady glucose monitoring. CGMs are used by individuals who treat their diabetes with insulin, for example people with sort 1 diabetes, type 2 diabetes, or different sorts of diabetes, comparable to gestational diabetes. Approved CGMs use an enzymatic know-how which reacts with glucose molecules in the body's interstitial fluid to generate an electric current that is proportional to glucose concentration. Data about glucose focus is then relayed from a transmitter attached to the sensor, BloodVitals wearable to a receiver that displays the information to the consumer. Continuous glucose monitoring is gaining in reputation for BloodVitals SPO2 a wide range of reasons. Traditional fingerstick testing measures blood glucose levels at only a single point in time. CGM enables customers to see blood glucose levels regularly, as well as developments in blood glucose ranges over time.

CGM is extra handy and fewer painful than conventional fingerstick testing. Some research have demonstrated that CGM customers spend much less time in hypoglycemia or with lower glycated hemoglobin, both of which are favorable outcomes. Continuous glucose displays seem to decrease hemoglobin A1c levels more than simply monitoring with capillary blood testing, significantly when CGM is utilized by individuals with poorly controlled diabetes and combined with using an integrated insulin pump. However, a Cochrane systematic overview found limited and conflicting evidence of the effectiveness of continuous glucose monitoring methods in kids, adults, and users with poorly managed diabetes. A meta-analysis of 25 randomised managed trials found that CGM-based mostly feedback to assist habits change modestly reduces glycated hemoglobin levels and will increase time-in-range in individuals with and with out diabetes. CGM methods should not sufficiently accurate for detecting hypoglycemia, a standard aspect-impact of diabetes treatment. This is particularly problematic because some devices have alarm capabilities to warn customers about a hypoglycemic situation, and other people might depend on those alarms.

However, the Cochrane systematic evaluate showed that the use of continuous glucose screens did not improve the risk of hypoglycemia or ketoacidosis. Some manufacturers warn users about relying solely on CGM measurements. The National Institute for Health and Care Excellence recommends validating hypoglycaemic values with fingerprick testing. Compression lows or stress-induced sensitivity attenuations (PISA) are false hypoglycemic readings resulting from strain applied at the CGM site. These will be brought on by the person sleeping or BloodVitals SPO2 sitting on the sensor, and BloodVitals wearable should end in incorrect treatment. Another limitation of CGM is that glucose levels are taken from the body's interstitial fluid rather than from the blood. Because it takes time for glucose to travel from the bloodstream into the interstitial fluid, there is an inherent lag between precise blood glucose level and the level measured by the CGM. This lag time varies by each user and device, however it is normally 5 to 20 minutes. The unique Freestyle Libre monitor launched by Abbott Diabetes Care in 2015 was described as doing "flash glucose monitoring," with a disposable 14-day sensor probe beneath the skin (as with different CGM sensors), but factory-calibrated with out requiring calibration towards a fingerstick glucose check.

The sensor BloodVitals wearable measures the glucose degree of interstitial fluids (as a proxy for blood sugar ranges) continuously; up to eight hours of these readings, averaged over each 15-minute period, BloodVitals SPO2 are saved in the sensor BloodVitals wearable unit, not like most different CGM techniques, which use a wireless hyperlink (sometimes Bluetooth) to an external system for each reading. Data saved within the sensor are transmitted on demand BloodVitals wearable to a "reader" held inside a centimeter or two of the sensor unit, using near-discipline communication (NFC) expertise. As only eight hours value of knowledge will be stored, BloodVitals health downloads must not be spaced greater than eight hours apart. Differences in US insurance coverage protection favoring "flash glucose monitoring" over "continuous glucose monitoring" have been a bonus to early adoption of Abbott's cheaper system. In the UK, flash glucose monitors and sensors are available to many patients without cost on the National Health Service (NHS). The later Freestyle Libre 2 model of Abbott's machine uses different, incompatible, sensors.

It may be programmed to transmit a low blood sugar (hypoglycemia) or high sugar warning via Bluetooth to a close by machine and, BloodVitals review as of 2023, transmits glucose readings by way of Bluetooth on a 60-second basis successfully making a CGM and not a flash glucose monitor. The first CGM system was accredited by the FDA in 1999. Continued growth has extended the size of time sensors may be worn, options for receiving and studying data, and settings for alerting customers to high and low glucose levels. The primary iteration of the Medtronic MiniMed took glucose readings each ten seconds with common readings reported each 5 minutes. Sensors could possibly be worn for as much as 72 hours. A second system, developed by Dexcom, was accredited in 2006. The sensor was accredited to be used for up to seventy two hours, and the receiver needed to be within five toes for transmission of knowledge. In 2008, the third model was approved, BloodVitals wearable Abbott Laboratories' Freestyle Navigator. Sensors might be worn for up to 5 days.